The United Kingdom’s ambitious plans to foster growth within its vital life sciences sector are facing significant headwinds, with industry…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The United States Food and Drug Administration (FDA) embarked on a bold new initiative in June 2025 with the announcement…
Read More
Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital, and industry converge at Campus Grand Parc.
The recent inauguration of THE HIVE at Campus Grand Parc in Paris marks a significant inflection point for Europe’s oncology…
Read More
Top Pharma Companies Set Sustainability Goals, But Emissions Are Still Increasing
The global healthcare industry, a cornerstone of human well-being, paradoxically carries a substantial environmental burden, contributing an estimated 4.4% of…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Salesforce Lands 140 Life Sciences Clients, Pitches ‘Headless’ AI to Pharma
As Peter Gassner, CEO of Veeva Systems, the long-established cloud software provider dominating the life sciences industry, prepared to take…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion
Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potentially life-changing treatments for rare diseases are currently languishing on the shelves of pharmaceutical companies, dormant and…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read MoreYOU MAY HAVE MISSED
